| Indacaterol EfectIveness In COPD Patients With Tuberculosis History (NCT01778062) | Novartis Pharmaceuticals | 2013-02-01 |
| An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (NCT01736540) | Novartis Pharmaceuticals | 2013-02-01 |
| Ext. Long-term Safety Study in CF Patients: Single Arm TIP (NCT01775137) | Novartis Pharmaceuticals | 2013-02-01 |
| Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (NCT01589237) | Novartis Pharmaceuticals | 2013-02-01 |
| An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (NCT01743560) | Novartis Pharmaceuticals | 2013-01-31 |
| Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy (NCT01723072) | Novartis Pharmaceuticals | 2013-01-23 |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (NCT01682083) | Novartis Pharmaceuticals | 2013-01-08 |
| Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome (NCT01637272) | Novartis Pharmaceuticals | 2013-01-08 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients (NCT02089087) | Novartis Pharmaceuticals | 2013-01-07 |
| Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (NCT01758380) | Novartis Pharmaceuticals | 2013-01-01 |
| An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (NCT01676948) | Novartis Pharmaceuticals | 2013-01-01 |
| Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma (NCT01691807) | Novartis Pharmaceuticals | 2013-01-01 |
| Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (NCT01688882) | Novartis Pharmaceuticals | 2013-01-01 |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (NCT01843348) | Novartis Pharmaceuticals | 2012-12-27 |
| Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (NCT01625182) | Novartis Pharmaceuticals | 2012-12-22 |
| Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (NCT01698905) | Novartis Pharmaceuticals | 2012-12-20 |
| Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (NCT01665144) | Novartis Pharmaceuticals | 2012-12-20 |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer (NCT01685138) | Novartis Pharmaceuticals | 2012-12-20 |
| Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , (NCT01526889) | Novartis Pharmaceuticals | 2012-12-20 |
| BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) (NCT01750918) | Novartis Pharmaceuticals | 2012-12-19 |
| A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis (NCT01730248) | Novartis Pharmaceuticals | 2012-12-18 |
| Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (NCT01594281) | Novartis Pharmaceuticals | 2012-12-11 |
| Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (NCT01709838) | Novartis Pharmaceuticals | 2012-12-06 |
| A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (NCT01647789) | Novartis Pharmaceuticals | 2012-12-04 |
| Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma (NCT01716754) | Novartis Pharmaceuticals | 2012-12-01 |
| A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation (NCT01712516) | Novartis Pharmaceuticals | 2012-12-01 |
| Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension (NCT01692301) | Novartis Pharmaceuticals | 2012-12-01 |
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (NCT01613950) | Novartis Pharmaceuticals | 2012-12-01 |
| A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (NCT01625377) | Novartis Pharmaceuticals | 2012-12-01 |
| Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD). (NCT01624636) | Novartis Pharmaceuticals | 2012-12-01 |
| A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (NCT01708161) | Novartis Pharmaceuticals | 2012-11-27 |
| LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (NCT01685060) | Novartis Pharmaceuticals | 2012-11-26 |
| Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (NCT01283542) | Novartis Pharmaceuticals | 2012-11-26 |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations (NCT01646125) | Novartis Pharmaceuticals | 2012-11-23 |
| A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT01602315) | Novartis Pharmaceuticals | 2012-11-12 |
| Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD (NCT01617681) | Novartis Pharmaceuticals | 2012-11-08 |
| NVA237 Versus Placebo 12-week Efficacy Study (NCT01709864) | Novartis Pharmaceuticals | 2012-11-01 |
| A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma (NCT01652547) | Novartis Pharmaceuticals | 2012-11-01 |
| Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control (NCT01715311) | Novartis Pharmaceuticals | 2012-11-01 |
| NVA237 BID Versus Placebo Twelve-week Efficacy Study (NCT01715298) | Novartis Pharmaceuticals | 2012-11-01 |
| A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 (NCT01709903) | Novartis Pharmaceuticals | 2012-11-01 |
| Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01636076) | Novartis Pharmaceuticals | 2012-11-01 |
| BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (NCT01658436) | Novartis Pharmaceuticals | 2012-11-01 |
| A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. (NCT01727141) | Novartis Pharmaceuticals | 2012-11-01 |
| Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (NCT01699685) | Novartis Pharmaceuticals | 2012-11-01 |
| Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (NCT01686932) | Novartis Pharmaceuticals | 2012-11-01 |
| A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma (NCT01703312) | Novartis Pharmaceuticals | 2012-11-01 |
| Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease (NCT01731990) | Novartis Pharmaceuticals | 2012-10-30 |
| A Phase I Study of Oral BGJ398 in Asian Patients (NCT01697605) | Novartis Pharmaceuticals | 2012-10-19 |
| 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (NCT01649375) | Novartis Pharmaceuticals | 2012-10-18 |
| Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (NCT01636687) | Novartis Pharmaceuticals | 2012-10-17 |
| Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients (NCT01649427) | Novartis Pharmaceuticals | 2012-10-17 |
| Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (NCT01673646) | Novartis Pharmaceuticals | 2012-10-16 |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi (NCT01633060) | Novartis Pharmaceuticals | 2012-10-03 |
| Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects (NCT01631864) | Novartis Pharmaceuticals | 2012-10-01 |
| Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (NCT01770379) | Novartis Pharmaceuticals | 2012-10-01 |
| Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation (NCT01610037) | Novartis Pharmaceuticals | 2012-10-01 |
| A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber (NCT01804400) | Novartis Pharmaceuticals | 2012-10-01 |
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT01628913) | Novartis Pharmaceuticals | 2012-10-01 |
| Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (NCT01598987) | Novartis Pharmaceuticals | 2012-10-01 |
| A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (NCT01578330) | Novartis Pharmaceuticals | 2012-10-01 |
| Pharmacokinetics of BAF312 in Patients With Hepatic Impairment (NCT01565902) | Novartis Pharmaceuticals | 2012-10-01 |
| Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg (NCT01619878) | Novartis Pharmaceuticals | 2012-10-01 |
| Long Term Safety Study of NVA237 vs QAB149 in COPD Patients (NCT01697696) | Novartis Pharmaceuticals | 2012-10-01 |
| A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation (NCT01682863) | Novartis Pharmaceuticals | 2012-10-01 |
| Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer (NCT01602406) | Novartis Pharmaceuticals | 2012-09-21 |
| A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (NCT05044026) | Novartis Pharmaceuticals | 2012-09-20 |
| 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (NCT01640951) | Novartis Pharmaceuticals | 2012-09-16 |
| 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study (NCT02465203) | Novartis Pharmaceuticals | 2012-09-06 |
| Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension (NCT01601470) | Novartis Pharmaceuticals | 2012-09-01 |
| Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease (NCT01593527) | Novartis Pharmaceuticals | 2012-09-01 |
| BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia (NCT01669174) | Novartis Pharmaceuticals | 2012-09-01 |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients (NCT01634061) | Novartis Pharmaceuticals | 2012-09-01 |
| Human Urine Sample Collection for Alport Nephropathy Biomarker Studies (NCT01602835) | Novartis Pharmaceuticals | 2012-09-01 |
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (NCT01690871) | Novartis Pharmaceuticals | 2012-09-01 |
| A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers (NCT01621633) | Novartis Pharmaceuticals | 2012-09-01 |
| A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients (NCT01730768) | Novartis Pharmaceuticals | 2012-09-01 |
| A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (NCT01705236) | Novartis Pharmaceuticals | 2012-08-20 |
| Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (NCT01544491) | Novartis Pharmaceuticals | 2012-08-17 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (NCT01633112) | Novartis Pharmaceuticals | 2012-08-09 |
| Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (NCT01610284) | Novartis Pharmaceuticals | 2012-08-07 |
| Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine (NCT01663233) | Novartis Pharmaceuticals | 2012-08-01 |
| A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer (NCT01617668) | Novartis Pharmaceuticals | 2012-08-01 |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (NCT01572727) | Novartis Pharmaceuticals | 2012-08-01 |
| Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension (NCT01681576) | Novartis Pharmaceuticals | 2012-08-01 |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients (NCT01613976) | Novartis Pharmaceuticals | 2012-08-01 |
| Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. (NCT01649466) | Novartis Pharmaceuticals | 2012-08-01 |
| Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension (NCT01615198) | Novartis Pharmaceuticals | 2012-08-01 |
| Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (NCT01585272) | Novartis Pharmaceuticals | 2012-08-01 |
| Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma (NCT01609478) | Novartis Pharmaceuticals | 2012-08-01 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients (NCT02190604) | Novartis Pharmaceuticals | 2012-07-31 |
| Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma (NCT01649778) | Novartis Pharmaceuticals | 2012-07-19 |
| Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients (NCT01646671) | Novartis Pharmaceuticals | 2012-07-01 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients (NCT02137889) | Novartis Pharmaceuticals | 2012-07-01 |
| Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma (NCT01555151) | Novartis Pharmaceuticals | 2012-07-01 |
| A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors (NCT01626209) | Novartis Pharmaceuticals | 2012-07-01 |
| A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer (NCT01598077) | Novartis Pharmaceuticals | 2012-07-01 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
| A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome (NCT01514461) | Novartis Pharmaceuticals | 2012-07-01 |
| Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) (NCT01614886) | Novartis Pharmaceuticals | 2012-07-01 |